Beam Therapeutics disclosed early Phase 1/2 base editing data on a rare disease program, while also announcing it will collaborate with Enodia—an example of how gene-editing players are pairing platform progress with targeted pathway partnerships. On the manufacturing side, lipid-nanoparticle approaches are emerging as an alternative to viral workflows: MIT engineers reported lipid nanoparticles engineered to reprogram NK cells inside the body into CAR-bearing cancer killers in living animals. Together, the updates highlight two parallel execution paths for cell therapies—editing and in vivo programming—both aimed at reducing manufacturing friction while improving consistency and access.